Lamees Hegazy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lamees Hegazy has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Bahaa Elgendy
Washington University in St. Louis
13 shared publications - Thomas P. Burris
University of Florida
5 shared publications - Brian N. Finck
Division of Geriatrics and Nutritional Science, Washington University School of Medicine, St. Louis, USA
4 shared publications - Mohamed Elagawany
University of Health Sciences and Pharmacy in St. Louis
3 shared publications Mohammad Homaidur Rahman
Center for Clinical Pharmacology
3 shared publicationsAurore-Cecile Valfort
Department of Cellular and Systems Pharmacology
2 shared publications
Latest Publications
- 25 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 16036-16060
Discovery of Imine-Modified Quinazolinyl Sulfonamides as Dual hCA IX/XII Inhibitors with Potent Antiproliferative Activity
Tumor-associated carbonic anhydrases (hCA IX and XII) drive cancer survival under hypoxia. However, developing therapeutics that avoid the ubiquitous physiological isoforms (hCA I and II) to prevent off-target liabilities remains challenging. Herein, we report the design, synthesis, and evaluation of novel 3,4-dihydroquinazoline-based benzenesulfonamides as selective hCA inhibitors. Structure–activity relationship and molecular dynamics studies demonstrated that converting primary amines to imine derivatives successfully abolished hCA I activity while retaining nanomolar potency against hCA IX and XII. Specifically, BE21349 showed high affinity for hCA IX (KI = 61.8 nM) and hCA XII (KI= 40.5 nM), exhibiting over 33- and 51-fold selectivity for these respective isoforms over hCA I (KI = 2090 nM). Antiproliferative screening identified the hCA I-inactive derivatives BE21349 and BE21417 as potent multitarget agents across the NCI-60 panel. Notably, BE21417 exhibited a nearly 6-fold preference for hCA XII over hCA II, representing a promising targeted anticancer scaffold.
- 25 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 16036-16060
Discovery of Imine-Modified Quinazolinyl Sulfonamides as Dual hCA IX/XII Inhibitors with Potent Antiproliferative Activity
Tumor-associated carbonic anhydrases (hCA IX and XII) drive cancer survival under hypoxia. However, developing therapeutics that avoid the ubiquitous physiological isoforms (hCA I and II) to prevent off-target liabilities remains challenging. Herein, we report the design, synthesis, and evaluation of novel 3,4-dihydroquinazoline-based benzenesulfonamides as selective hCA inhibitors. Structure–activity relationship and molecular dynamics studies demonstrated that converting primary amines to imine derivatives successfully abolished hCA I activity while retaining nanomolar potency against hCA IX and XII. Specifically, BE21349 showed high affinity for hCA IX (KI = 61.8 nM) and hCA XII (KI= 40.5 nM), exhibiting over 33- and 51-fold selectivity for these respective isoforms over hCA I (KI = 2090 nM). Antiproliferative screening identified the hCA I-inactive derivatives BE21349 and BE21417 as potent multitarget agents across the NCI-60 panel. Notably, BE21417 exhibited a nearly 6-fold preference for hCA XII over hCA II, representing a promising targeted anticancer scaffold.
- Open Access
Pharmacological rescue of mitochondrial dysfunction, neurite degeneration, and premature death of ALS and AD iPSC-derived neurons
Mitochondrial (MT) dysfunction is a key driver of ALS pathology. Without a healthy MT system, motor neurons (MN) function at sub-optimal levels and die. In addition, other effects of ALS, like axon/dendrite degeneration, may occur from a pathophysiological cascade spurred by MT dysfunction. A phenotypic screen identified Dipyridamole (DPM), an FDA-approved and safe drug, as having extraordinary effects on ALS patient induced pluripotent stem cell (iPSC)-derived MNs. The drug prevented MT fragmentation, loss of MT content, impaired MT bioenergetics, axon/dendrite degeneration, and premature MN death, extending neuronal survival by more than fivefold. Importantly, its efficacy extended across iPSC-derived neurons representing two different familial forms of ALS (C9orf72, TDP43) and Alzheimer’s disease (PSEN1), implying broad neuroprotection across ALS forms and other neurodegenerative diseases. DPM increased MT respiration and pyruvate uptake in a mechanism requiring the Mitochondrial Pyruvate Carrier (MPC), mechanistically explaining its biological activities. Thus, DPM is a promising drug to repurpose or refine for treating neurodegenerative diseases or other diseases that would benefit by augmenting pyruvate uptake into MT. Teaser: Dipyridamole, an FDA-approved drug, restores mitochondrial function and protects neurons in ALS and Alzheimer’s disease.
Open AccessPharmacological rescue of mitochondrial dysfunction, neurite degeneration, and premature death of ALS and AD iPSC-derived neurons
Mitochondrial (MT) dysfunction is a key driver of ALS pathology. Without a healthy MT system, motor neurons (MN) function at sub-optimal levels and die. In addition, other effects of ALS, like axon/dendrite degeneration, may occur from a pathophysiological cascade spurred by MT dysfunction. A phenotypic screen identified Dipyridamole (DPM), an FDA-approved and safe drug, as having extraordinary effects on ALS patient induced pluripotent stem cell (iPSC)-derived MNs. The drug prevented MT fragmentation, loss of MT content, impaired MT bioenergetics, axon/dendrite degeneration, and premature MN death, extending neuronal survival by more than fivefold. Importantly, its efficacy extended across iPSC-derived neurons representing two different familial forms of ALS (C9orf72, TDP43) and Alzheimer’s disease (PSEN1), implying broad neuroprotection across ALS forms and other neurodegenerative diseases. DPM increased MT respiration and pyruvate uptake in a mechanism requiring the Mitochondrial Pyruvate Carrier (MPC), mechanistically explaining its biological activities. Thus, DPM is a promising drug to repurpose or refine for treating neurodegenerative diseases or other diseases that would benefit by augmenting pyruvate uptake into MT. Teaser: Dipyridamole, an FDA-approved drug, restores mitochondrial function and protects neurons in ALS and Alzheimer’s disease.
- 23 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure-activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC50 = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t1/2 = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- 23 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure-activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC50 = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t1/2 = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 20-40
Structural Pharmacology of Estrogen-Related Receptors
Estrogen-related receptors (ERRs) are orphan nuclear receptors critical to the regulation of energy metabolism, mitochondrial biogenesis, and tissue-specific transcriptional programs. This review provides a comprehensive structural analysis of ERR isoforms (ERRα, ERRβ, and ERRγ), emphasizing insights from X-ray crystallography and NMR studies. We discuss the ligand-binding domains (LBDs), coactivator and corepressor interactions, and the molecular mechanisms underlying ligand-induced agonism or antagonism. Structural comparisons with estrogen receptors (ERs) reveal key amino acid determinants for ligand selectivity and functional activity. Furthermore, we highlight the development of isoform-selective synthetic ligands, including inverse agonists such as GSK5182, DN200434, and DN201000, with therapeutic potential in metabolic, neurodegenerative, and oncologic diseases. This synthesis of structural data provides a framework for rational drug design targeting ERRs, supporting the development of selective modulators to manipulate ERR signaling in a tissue- and disease-specific manner.
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 20-40
Structural Pharmacology of Estrogen-Related Receptors
Estrogen-related receptors (ERRs) are orphan nuclear receptors critical to the regulation of energy metabolism, mitochondrial biogenesis, and tissue-specific transcriptional programs. This review provides a comprehensive structural analysis of ERR isoforms (ERRα, ERRβ, and ERRγ), emphasizing insights from X-ray crystallography and NMR studies. We discuss the ligand-binding domains (LBDs), coactivator and corepressor interactions, and the molecular mechanisms underlying ligand-induced agonism or antagonism. Structural comparisons with estrogen receptors (ERs) reveal key amino acid determinants for ligand selectivity and functional activity. Furthermore, we highlight the development of isoform-selective synthetic ligands, including inverse agonists such as GSK5182, DN200434, and DN201000, with therapeutic potential in metabolic, neurodegenerative, and oncologic diseases. This synthesis of structural data provides a framework for rational drug design targeting ERRs, supporting the development of selective modulators to manipulate ERR signaling in a tissue- and disease-specific manner.
- Open Access
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure–activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC₅₀ = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t₁/₂ = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure–activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC₅₀ = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t₁/₂ = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- Open Access
- 11 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117150
Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
- 11 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117150
Open AccessAdvancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
- Open Access
- 10 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Mechanism of antagonist ligand binding to REV-ERBα
REV-ERBα, a therapeutically promising nuclear hormone receptor, plays a crucial role in regulating various physiological processes such as the circadian clock, inflammation, and metabolism. However, the availability of chemical probes to investigate the pharmacology of this receptor is limited, with SR8278 being the only identified synthetic antagonist. Moreover, no X-ray crystal structures are currently available that demonstrate the binding of REV-ERBα to antagonist ligands. This lack of structural information impedes the development of targeted therapeutics. To address this issue, we employed Gaussian accelerated molecular dynamics (GaMD) simulations to investigate the binding pathway of SR8278 to REV-ERBα. For comparison, we also used GaMD to observe the ligand binding process of STL1267, for which an X-ray structure is available. GaMD simulations successfully captured the binding of both ligands to the receptor’s orthosteric site and predicted the ligand binding pathway and important amino acid residues involved in the antagonist SR8278 binding. This study highlights the effectiveness of GaMD in investigating protein–ligand interactions, particularly in the context of drug recognition for nuclear hormone receptors.
- 10 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessMechanism of antagonist ligand binding to REV-ERBα
REV-ERBα, a therapeutically promising nuclear hormone receptor, plays a crucial role in regulating various physiological processes such as the circadian clock, inflammation, and metabolism. However, the availability of chemical probes to investigate the pharmacology of this receptor is limited, with SR8278 being the only identified synthetic antagonist. Moreover, no X-ray crystal structures are currently available that demonstrate the binding of REV-ERBα to antagonist ligands. This lack of structural information impedes the development of targeted therapeutics. To address this issue, we employed Gaussian accelerated molecular dynamics (GaMD) simulations to investigate the binding pathway of SR8278 to REV-ERBα. For comparison, we also used GaMD to observe the ligand binding process of STL1267, for which an X-ray structure is available. GaMD simulations successfully captured the binding of both ligands to the receptor’s orthosteric site and predicted the ligand binding pathway and important amino acid residues involved in the antagonist SR8278 binding. This study highlights the effectiveness of GaMD in investigating protein–ligand interactions, particularly in the context of drug recognition for nuclear hormone receptors.
- 29 March 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (4) , 756-771
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Repetitive physical exercise induces physiological adaptations in skeletal muscle that improves exercise performance and is effective for the prevention and treatment of several diseases. Genetic evidence indicates that the orphan nuclear receptors estrogen receptor-related receptors (ERRs) play an important role in skeletal muscle exercise capacity. Three ERR subtypes exist (ERRα, β, and γ), and although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity. Additionally, there are limited synthetic agonists that can be used to target ERRs in vivo. Here, we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα. Additionally, SLU-PP-332 has sufficient pharmacokinetic properties to be used as an in vivo chemical tool. SLU-PP-332 increases mitochondrial function and cellular respiration in a skeletal muscle cell line. When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. We also observed that SLU-PP-332 induced an ERRα-specific acute aerobic exercise genetic program, and the ERRα activation was critical for enhancing exercise endurance in mice. These data indicate the feasibility of targeting ERRα for the development of compounds that act as exercise mimetics that may be effective in the treatment of numerous metabolic disorders and to improve muscle function in the aging.
- 29 March 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (4) , 756-771
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Repetitive physical exercise induces physiological adaptations in skeletal muscle that improves exercise performance and is effective for the prevention and treatment of several diseases. Genetic evidence indicates that the orphan nuclear receptors estrogen receptor-related receptors (ERRs) play an important role in skeletal muscle exercise capacity. Three ERR subtypes exist (ERRα, β, and γ), and although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity. Additionally, there are limited synthetic agonists that can be used to target ERRs in vivo. Here, we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα. Additionally, SLU-PP-332 has sufficient pharmacokinetic properties to be used as an in vivo chemical tool. SLU-PP-332 increases mitochondrial function and cellular respiration in a skeletal muscle cell line. When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. We also observed that SLU-PP-332 induced an ERRα-specific acute aerobic exercise genetic program, and the ERRα activation was critical for enhancing exercise endurance in mice. These data indicate the feasibility of targeting ERRα for the development of compounds that act as exercise mimetics that may be effective in the treatment of numerous metabolic disorders and to improve muscle function in the aging.
- Open Access
- 21 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB
The nuclear receptor REV-ERB plays an important role in a range of physiological processes. REV-ERB behaves as a ligand-dependent transcriptional repressor and heme has been identified as a physiological agonist. Our current understanding of how ligands bind to and regulate transcriptional repression by REV-ERB is based on the structure of heme bound to REV-ERB. However, porphyrin (heme) analogues have been avoided as a source of synthetic agonists due to the wide range of heme binding proteins and potential pleotropic effects. How non-porphyrin synthetic agonists bind to and regulate REV-ERB has not yet been defined. Here, we characterize a high affinity synthetic REV-ERB agonist, STL1267, and describe its mechanism of binding to REV-ERB as well as the method by which it recruits transcriptional corepressor both of which are unique and distinct from that of heme-bound REV-ERB.
- 21 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Open AccessStructural basis of synthetic agonist activation of the nuclear receptor REV-ERB
The nuclear receptor REV-ERB plays an important role in a range of physiological processes. REV-ERB behaves as a ligand-dependent transcriptional repressor and heme has been identified as a physiological agonist. Our current understanding of how ligands bind to and regulate transcriptional repression by REV-ERB is based on the structure of heme bound to REV-ERB. However, porphyrin (heme) analogues have been avoided as a source of synthetic agonists due to the wide range of heme binding proteins and potential pleotropic effects. How non-porphyrin synthetic agonists bind to and regulate REV-ERB has not yet been defined. Here, we characterize a high affinity synthetic REV-ERB agonist, STL1267, and describe its mechanism of binding to REV-ERB as well as the method by which it recruits transcriptional corepressor both of which are unique and distinct from that of heme-bound REV-ERB.
- Open Access
- 2 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 365
Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
The mitochondrial pyruvate carrier (MPC) is an inner-mitochondrial membrane protein complex that has emerged as a drug target for treating a variety of human conditions. A heterodimer of two proteins, MPC1 and MPC2, comprises the functional MPC complex in higher organisms; however, the structure of this complex, including the critical residues that mediate binding of pyruvate and inhibitors, remain to be determined. Using homology modeling, we identified a putative substrate-binding cavity in the MPC dimer. Three amino acid residues (Phe66 (MPC1) and Asn100 and Lys49 (MPC2)) were validated by mutagenesis experiments to be important for substrate and inhibitor binding. Using this information, we developed a pharmacophore model and then performed a virtual screen of a chemical library. We identified five new non-indole MPC inhibitors, four with IC50 values in the nanomolar range that were up to 7-fold more potent than the canonical inhibitor UK-5099. These novel compounds possess drug-like properties and complied with Lipinski’s Rule of Five. They are predicted to have good aqueous solubility, oral bioavailability, and metabolic stability. Collectively, these studies provide important information about the structure-function relationships of the MPC complex and for future drug discovery efforts targeting the MPC.
- 2 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 365
Open AccessIdentification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
The mitochondrial pyruvate carrier (MPC) is an inner-mitochondrial membrane protein complex that has emerged as a drug target for treating a variety of human conditions. A heterodimer of two proteins, MPC1 and MPC2, comprises the functional MPC complex in higher organisms; however, the structure of this complex, including the critical residues that mediate binding of pyruvate and inhibitors, remain to be determined. Using homology modeling, we identified a putative substrate-binding cavity in the MPC dimer. Three amino acid residues (Phe66 (MPC1) and Asn100 and Lys49 (MPC2)) were validated by mutagenesis experiments to be important for substrate and inhibitor binding. Using this information, we developed a pharmacophore model and then performed a virtual screen of a chemical library. We identified five new non-indole MPC inhibitors, four with IC50 values in the nanomolar range that were up to 7-fold more potent than the canonical inhibitor UK-5099. These novel compounds possess drug-like properties and complied with Lipinski’s Rule of Five. They are predicted to have good aqueous solubility, oral bioavailability, and metabolic stability. Collectively, these studies provide important information about the structure-function relationships of the MPC complex and for future drug discovery efforts targeting the MPC.